Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.31 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24686932 | 1.00 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL8921913 | 0.89 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL7148398 | 0.87 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL8695095 | 0.87 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL18090749 | 0.87 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL1783593 | 0.87 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL8696251 | 0.87 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12803859 | 0.87 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL17110046 | 0.87 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL4308897 | 0.87 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | PI4KA 3958/4885PI4K2B 4134/4885PI4K2A 4243/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | PI4KA 3958/4885PI4K2B 4134/4885PI4K2A 4243/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | PI4KA 4125/4885PI4K2B 4285/4885PI4K2A 4377/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | PI4KA 3958/4885PI4K2B 4134/4885PI4K2A 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.